Heska Corp (HSKA) 10-K Annual Report March 2017



Heska Corporation		Hayden IR:
John McMahon, Chief Financial Officer		Brett Maas, Managing Partner
970.619.3082		646.536.7331
investorrelations@heska.com		brett@haydenir.com

Heska Reports Record Quarter and Annual Results

Q4 Revenue Up 33% to $39.5 million; Q4 Net Income up 70%; Q4 EPS of $0.46

LOVELAND, CO, February 28, 2017 --

Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, today reported record financial results for its fourth quarter and year ended December 31, 2016.

Fourth Quarter 2016 Highlights with Prior Year Comparison:


•	Revenue up 33% to $39.5 million.


•	Operating income up 83% to $6.5 million.


•	Net income attributable to Heska up 70% to $3.5 million, or $0.46 per diluted share.

Full Year 2016 Highlights with Prior Year Comparison:


•	Revenue up 24% to $130.1 million.


•	Operating income up 93% to $16.5 million.


•	Net income attributable to Heska up 101% to $10.5 million, or $1.43 per diluted share.

Kevin Wilson, Heska’s Chief Executive Officer and President, commented, “The fourth quarter of 2016 was another record quarter that capped a record year. During our last earnings release I indicated that we were tracking a robust pipeline, gaining market share, and seeing continued net subscriber growth; all of which supported our view that we would beat our previous expectations. Today I am proud to share that the hard-working men and women of Heska delivered well. Imaging diagnostics had a record fourth quarter, and in blood diagnostics, Heska continued to gain market share in a sustainable fashion, with strong Reset program net subscriber and months under contract gains. And, in our vaccines, allergy, partner products and pharmaceuticals efforts, our teams and our partners did a fantastic job commercially and operationally. I am very pleased with our team’s 2016 performance.”

“Veterinary market indicators continue to point towards broad based growth in 2017, led by the diagnostics segment served by Heska,” added Mr. Wilson. “Specific to Heska, we are targeting growth from a mix of market share gains in existing markets, geographical and greenfield expansion, product line extensions, test menu additions, higher sales force density, healthy pricing, new partnerships and increased utilization from our thousands of subscribers as their own businesses grow. Successes in these initiatives are targeted to be meaningfully additive to Heska’s current baseline. Additionally, we anticipate finalizing the acquisition of the remainder of the Heska Imaging minority position that we don’t currently

The following information was filed by Heska Corp (HSKA) on Tuesday, February 28, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1038133/000103813317000018/heska-12312016x10k.htm

View differences made from one year to another to evaluate Heska Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Heska Corp.

Continue

Assess how Heska Corp's management team is paid from their Annual Proxy

Heska Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Heska Corp provided additional information to their SEC Filing as exhibits

Exhibit 3: Articles Of Incorporation

Exhibit 10.1: Material Contract

Exhibit 10.2: Material Contract

Exhibit 10.3: Material Contract

Exhibit 10.4: Material Contract

Exhibit 10.5: Material Contract

Exhibit 10.6: Material Contract

Exhibit 10.8: Material Contract

Exhibit 10.9: Material Contract

Exhibit 10.10: Material Contract

Exhibit 10.11: Material Contract

Exhibit 10.12: Material Contract

Exhibit 10.15: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: HSKA
CIK: 1038133
Form Type: 10-K Annual Report
Accession Number: 0001038133-17-000018
Submitted to the SEC: Fri Mar 03 2017 9:04:49 PM EST
Accepted by the SEC: Mon Mar 06 2017
Period: Saturday, December 31, 2016
Industry: Biological Products No Disgnostic Substances